Cencora agreed with Kite, a Gilead company, to distribute Kite’s FDA-approved CAR T-cell therapies Yescarta and Tecartus across the U.S. The partnership is intended to expand patient access at authorized treatment centers, including health systems and community oncology practices. The companies said Cencora’s specialty distribution infrastructure will reduce provider administrative burden, including order management, as Kite grows its treatment center network. Kite’s U.S. leadership framed the deal as ensuring every eligible patient can access therapies where appropriate. With CAR T administration dependent on specialized centers and complex logistics, distribution partnerships are increasingly seen as levers for scaling clinical availability without adding operational friction for treatment sites.